TrustNetwork & Supply Chain

USA

Pharmaceutical, Biopharmaceutical, Others

Regulatory > Regulatory affairs, Regulatory > New Drug Application, Business consulting > Import, export

David Parkes, Ph D.

- Research Pharmacology Leader and Consultant in the fields of preclinical pharmacology (diabetes, obesity, liver and cardiovascular disease; Regulatory document preparation and review)
- Scientific strategy expert on drug development for metabolic diseases
- Medical and scientific education expert


- Biotechnology Professional with extensive drug development and preclinical pharmacology experience in the fields of diabetes, obesity, NASH and cardiovascular disease - led preclinical development of exenatide, a first-in-class treatment for Type 2 diabetes, now approved worldwide as Byetta and Bydureon
- Specialties: Diabetes, NASH and Obesity Drug Development, In Vivo Models, Regulatory Submissions (IND/NDA/CTD), Medical Affairs, Education and Document Planning, New Technology Evaluation, Scientific Communication, Life-Cycle Planning, Academic Outreach, Cross-functional Team Leadership.


Current representative relationships include:
- Prosciento - Preclinical Scientific Consultant
- Gilead - Senior Scientific Consultant
- Astra Zeneca - Senior Consultant
- Fractyl - Senior Consultant
- Prolynx - Senior Consultant